Trial Profile
Evaluation of the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Orally Administered ARMS-I Administered in Healthy Adults, Aged 18-45 Years
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 22 Apr 2019
Price :
$35
*
At a glance
- Drugs Cetylpyridinium (Primary)
- Indications Respiratory tract infections
- Focus Pharmacokinetics
- Acronyms ARMS-I
- 15 Apr 2019 Status changed from discontinued to withdrawn prior to enrolment.
- 27 Mar 2018 Status changed from recruiting to discontinued.
- 02 Feb 2017 New trial record